Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Clin Pediatr (Phila). 2020 Jan 31;59(4-5):388–395. doi: 10.1177/0009922820902433

Table 1.

Sample Demographics

Overall Sample (n = 64) Non-risk Sample (n = 38) Risk Sample (n = 26) t-test/χ2
Age, M (SD) 17.79 (1.21) 17.62 (1.13) 18.03 (1.31) −1.34 (p = .186)
Gender, n (%) .659 (p = .417)
 Female 33 (51.6) 18 (47.4) 15 (57.7)
 Male 31 (48.4) 20 (52.6) 11 (42.3)
Race/Ethnicity, n (%) 8.52 (p = .074)
 Non-Hispanic White 32 (50.0) 17 (44.7) 15 (57.7)
 Hispanic 6 (9.4) 3 (7.9) 3 (11.5)
 Black or African American 23 (35.9) 18 (47.4) 5 (19.2)
 Asian 1 (1.6) 0 1 (3.9)
 Other 2 (3.1) 0 2 (7.7)
Education, n (%) 6.10 (p = .014)
 High School 41 (64.1) 29 (76.3) 12 (46.2)
 College 23 (35.9) 9 (23.7) 14 (53.8)
Living Situation, n (%) 5.53 (p = .019)
 At home 51 (79.7) 34 (89.5) 17 (65.4)
 Away from home 13 (20.3) 4 (10.5) 9 (34.6)
HbA1c, M (SD) 8.89 (2.41) 8.83 (2.56) 8.97 (2.20) −.229 (p = .820)
Frequency of Blood Glucose Checks, M (SD) 3.54 (2.35) 3.71 (2.26) 3.30 (2.51) .616 (p = .541)
Disease Duration, years M (SD) 8.18 (4.32) 8.01 (4.72) 8.42 (3.76) −.360 (p = .720)
Regimen, n (%) 1.08 (p = .583)
 Pump 22 (34.4) 12 (31.6) 10 (38.5)
 Basal/Bolus 20 (31.3) 11 (28.9) 9 (34.6)
 Fixed Injections 22 (34.4) 15 (39.5) 7 (26.9)

Note. Risk sample is comprised of participants endorsing substance use within the past 30 days of their clinic visit.